Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
7 Results Found
AHA Letter of Support for the Rolling Active Pharmaceutical Ingredient and Drug, or RAPID, Reserve Act of 2023
Pharmaceutical shortages and supply chain failures can have a devastating impact on patients. The RAPID Reserve Act would establish a program to improve supply chain resiliency for critical generic drug products, ensuring adequate supply is available even in the event of a shortage.
AHA Letter of Support for the Pharmaceutical Supply Chain Risk Assessment Act of 2023
The Pharmaceutical Supply Chain Risk Assessment Act of 2023 would require a comprehensive risk assessment of the entire U.S. pharmaceutical supply chain. This overarching project will help provide critical information necessary to mitigate and prevent drug supply shortages.
AHA Letter of Support for the Mapping America's Pharmaceutical Supply Chain, or MAPS, Act of 2023
Hospitals and health systems share concern about chronic and increasing drug shortages that have serious consequences for patient safety, quality of care and access to therapies. Addressing drug shortages is complex and costly to hospitals and health systems in terms of staff time and other resources required to manage the shortages.
AHA to FTC Re: Request for Public Comment on the Impact of Pharmacy Benefit Managers’ Practice
The AHA urges the FTC to increase scrutiny on insurer-mandated white bagging policies, as well as the impact of PBM-negotiated rebates and other business practices on the 340B drug discount pricing program and overall drug prices and drug price increases.
AHA Expresses Concerns Regarding a Series of UnitedHealthcare Health Plan Coverage Policies
Letter to Centers for Medicare & Medicaid Services, expressing deep concerns regarding a series of UnitedHealthcare health plan coverage policies.
Regulatory Advisory: USP Chapters <797> and <800> New and Revised Compounding Standards
The United States Pharmacopeia (USP) in June 2019 released several new and revised pharmacy compounding standards. Specifically, USP published the final revised version of general chapter (Pharmaceutical Compounding of Sterile Preparations) to accompany the previous released general chapter (Hazardous Drugs Handling in Healthcare Settings).
Dec. 1 Compliance Date for USP <797> and USP <800> Standards Approaching
The United States Pharmacopeia (USP) recently finalized revisions to general chapter (Pharmaceutical Compounding and Sterile Preparations). In addition, USP in 2016 finalized a new general chapter, (Hazardous Drugs Handling in Healthcare Settings). Both general chapters have widespread implications for hospitals and health systems.